Levetiracetam Stada

Levetiracetam, the active ingredient in Levetiracetam Stada, is an anticonvulsant presented as a tablet for oral use. It is employed to control partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy through modulation of neuronal excitability.

GNH USA supplies Levetiracetam Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Customers benefit from reliable lead times and comprehensive documentation.

Levetiracetam is an antiepileptic drug used to treat several seizure types. - Partial‑onset seizures: reduces the frequency and severity of focal seizures, improving daily functioning. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy, decreasing injury risk. - Myoclonic seizures: controls sudden muscle jerks associated with myoclonic epilepsy, enhancing quality of life.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or imbalance. - Fatigue: persistent feeling of tiredness or reduced energy. - Headache: mild to moderate pressure or throbbing pain. - Nausea: feeling of queasiness, sometimes leading to vomiting.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome): skin blistering and mucosal involvement. - Mood changes including depression or suicidal thoughts: emerging or worsening psychiatric symptoms. - Hematologic abnormalities such as neutropenia: reduced white blood cell count increasing infection risk. - Hepatic dysfunction: elevated liver enzymes or jaundice indicating liver injury.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose based on creatinine clearance. - History of psychiatric disorders: monitor for mood changes or depression. - Concomitant CNS depressants: assess additive sedation risk. - Pregnancy: evaluate risk‑benefit ratio; limited data available. - Elderly patients: start at lower dose and titrate cautiously. - Store at ambient temperature: keep below 25 °C, protect from moisture in original container.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower levetiracetam exposure. - Phenytoin: may decrease levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: enhances central nervous system depression. - Opioids: may increase sedation when combined. - Other antiepileptics (e.g., valproate): monitor for additive side effects.